NovaBay Pharmaceuticals (NYSE:NBY) (NYSE: NBY) is a clinical-stage biotechnology company headquartered in Emeryville, California, specializing in the development and commercialization of novel anti-infective technologies. Leveraging its proprietary Aganocide platform, the company focuses on small molecule compounds designed to mimic the body’s natural immune defense by generating hypochlorous acid (HOCl) to target pathogens without promoting resistance. This platform underpins both its marketed products and late-stage clinical candidates for ocular and dermatological applications.
The company’s flagship marketed product, Avenova, is an ophthalmic hygiene solution cleared by the U.S. Food and Drug Administration for lid margin and lash hygiene to manage conditions such as blepharitis and dry eye disease. In addition, NovaBay distributes NeutroPhase, a wound care solution delivering stabilized HOCl for the management of chronic wounds, burns, and dermatological injuries. Both products are sold through a network of healthcare professionals, retail partners, and select international distributors across North America and other regions.
Founded in 2000, NovaBay has built a patent-protected pipeline of Aganocide-based candidates, including NVC-422, a topical anti-infective in clinical development for indications such as urinary tract infections and skin infections. The company employs a strategic regulatory and partnership approach to advance its clinical programs and expand its geographic reach, seeking collaborations to accelerate product adoption in new markets.
Under the leadership of President and Chief Executive Officer Scott J. Bohen, NovaBay continues to execute on its mission to deliver innovative anti-infective solutions that address unmet medical needs. The management team combines extensive experience in pharmaceutical development, regulatory affairs, and commercial operations as the company works toward broader market penetration of its Aganocide platform.
